Why the study?
Conventional fixed-dose beta-blocker strategies for AF rate control fail to account for dynamic individual variability in HR and response.
Does a wearable-based precision management system for adaptive atenolol dosing optimize rate control and minimize side effects in patients with atrial fibrillation compared to conventional fixed-dose strategies?
Does a wearable-based precision management system for adaptive atenolol dosing optimize rate control and minimize side effects in patients with atrial fibrillation compared to conventional fixed-dose strategies?
This paper proposes a conceptual framework for using wearable heart rate monitors and machine learning to guide real-time adaptive atenolol dosing for rate control in atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for wearable-ML adaptive atenolol dosing in AF; prospective trials needed before any clinical consideration.
Atrial fibrillation (AF) is a prevalent arrhythmia linked to increased risks of stroke, heart failure, and mortality. Conventional fixed-dose beta-blocker strategies for AF rate control, such as atenolol, fail to account for dynamic individual variability in heart rate (HR) and response. This paper introduces a conceptual framework for a wearable-based precision management system in AF, inspired by continuous glucose monitoring and precision hypertension models. The proposed system utilizes a wrist-worn HR monitor paired with a smartphone app to inform adaptive atenolol dosing in real-time. By employing machine learning for AF detection and adaptive algorithms to modulate dosing based on HR patterns, this approach aims to optimize rate control while minimizing side effects. A pilot study design
No takes yet. Share an insight, caveat, or question.
Edoardo Cervoni (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: